- Home
- JELD vs ALEC Comparison
JELD vs ALEC Comparison
Compare JELD & ALEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JELD | ALEC |
|---|---|---|
| Founded | 1960 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Forest Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 167.6M |
| IPO Year | 2016 | 2019 |
Fundamental Metrics
Financial Performance| Metric | JELD | ALEC |
|---|---|---|
| Price | $1.86 | $2.16 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $3.43 | ★ $4.83 |
| AVG Volume (30 Days) | ★ 1.5M | 1.0M |
| Earning Date | 05-04-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | $21,045,000.00 |
| Revenue This Year | N/A | $2.03 |
| Revenue Next Year | $2.06 | $29.87 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.93 | $1.09 |
| 52 Week High | $6.98 | $3.40 |
Technical Indicators
Market Signals| Indicator | JELD | ALEC |
|---|---|---|
| Relative Strength Index (RSI) | 66.72 | 65.10 |
| Support Level | $1.64 | $1.93 |
| Resistance Level | $2.06 | $2.64 |
| Average True Range (ATR) | 0.12 | 0.20 |
| MACD | 0.03 | 0.06 |
| Stochastic Oscillator | 80.67 | 95.83 |
Price Performance
Historical ComparisonAbout JELD JELD-WEN Holding Inc.
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
About ALEC Alector Inc.
Alector Inc is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases. The company advances a pipeline of product candidates including Nivisnebart (AL101/GSK4527226) for Alzheimer's disease, AL137 for Alzheimer's disease, AL050 for Parkinson's disease and Lewy body dementia, and AL064, an siRNA program targeting tau for Alzheimer's disease and other tauopathies, supported by its proprietary Alector Brain Carrier (ABC) platform designed to improve delivery of therapeutics across the blood-brain barrier.